Related Experiment Videos
[Treatment of apnea in prematurity]
1Service de médecine et réanimation néonatales, maternité régionale universitaire, Nancy, France.
Insights
Continuous monitoring and tailored treatment are crucial for premature infants experiencing apnea. Methylxanthines are a primary therapy, with other options available for treatment-resistant cases, ensuring infant safety and effective management.
Area of Science:
- Neonatal Medicine
- Pediatric Pulmonology
- Clinical Pharmacology
Context:
- Apnea of prematurity requires continuous monitoring for accurate diagnosis and treatment assessment.
- Understanding the pathophysiology of apnea is essential for selecting appropriate interventions.
- Current clinical practice emphasizes etiological treatment before symptomatic management.
Purpose:
- To outline the mandatory monitoring protocols for premature infants with apnea.
- To describe the stepwise treatment approach for apnea of prematurity.
- To detail the first-line and alternative therapeutic strategies based on apnea type.
Summary:
- Continuous monitoring defines apnea pathophysiology and guides treatment efficacy in premature infants.
- Methylxanthines are the first-line treatment for central apnea of prematurity.
- Doxapram or CPAP are adjuncts for treatment-resistant or obstructive apnea, with treatment cessation protocols detailed.
Impact:
- Optimized management strategies for apnea of prematurity.
- Improved assessment of treatment efficacy and infant tolerance.
- Reduced incidence and severity of apnea in vulnerable premature infants.
Abstract:
Continuous monitoring of premature infants with apnea is mandatory in order to define the pathophysiology and the type of apnea, and to assess the efficacy and tolerance of the treatment. Etiological treatment must be first considered before deciding on a symptomatic treatment adapted to the type of apnea. In our practice, methylxanthines are the first line treatment considering their efficiency on the 'central' component of apnea of prematurity. In case of treatment failure, doxapram or continuous positive pressure can be associated to methylxanthines, especially when obstructive apnea or hypoventilation are predominant. The first attempt to stop the treatment is undertaken 4 to 5 days after complete resolution of apnea, starting with the last treatment used, the monitoring being maintained 4 to 5 days in order to detect eventual new apnea.